Docetaxel rechallenge improves survival in patients with metastatic castration-resistant prostate cancer: a retrospective study
SC Hung, LW Chang, JR Li, SS Wang, CK Yang… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
SC Hung, LW Chang, JR Li, SS Wang… - In vivo (Athens …, 2021 - pubmed.ncbi.nlm.nih.gov
Background/aim Docetaxel has been widely used in metastatic Castration-resistant Prostate
Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate the …
Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate the …
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
SC Hung, LW Chang, JR Li, SS Wang, CK Yang… - IN VIVO, 2021 - ir.csmu.edu.tw
Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
SC HUNG, LIWEN CHANG, JRI LI, SS WANG… - In …, 2021 - search.ebscohost.com
Abstract Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
SC Hung, LW Chang, JR Li, SS Wang… - In Vivo (Athens …, 2021 - europepmc.org
Results Out of the 204 patients with mCRPC enrolled in the study, 24 patients received
docetaxel rechallenge and 180 did not. The median overall survival was 50.11 months in the …
docetaxel rechallenge and 180 did not. The median overall survival was 50.11 months in the …
[HTML][HTML] Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
SC HUNG, LIWEN CHANG, JRI LI, SS WANG… - In Vivo, 2021 - ncbi.nlm.nih.gov
Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
[PDF][PDF] Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
SC HUNG, LIWEN CHANG, JRI LI, SS WANG… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …